Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Hemoshear (Charlottesville, VA), a biotechnology company focused on the development of human and animal cell-based systems for discovery and assessment of drug compounds, closed a $4M Series C financing. Participants were not identified. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request […]

CryoXtract (Arlington, VA) a development-stage device company focused on an automated biobanking frozen sample aliquotter, closed a $3M Series A financing. Participants include Allied Minds. The 2Q11 OnBioVC Trend Analysis will be published on Tue 6 September. Advertising opportunities are still available. Reach >45,000 high-value targeted life science professionals on-line and in-print. Contact arubenstein@rnaventures.com for […]

Intrexon (Blacksburg, VA) a commercial-stage synthetic biology company focused on modular DNA control systems to enhance capabilities, improve safety and lower cost in human therapeutics, protein production, industrial products, agricultural biotechnology and animal science next generation synthetic biology company, closed a $100M Series E financing. Participants have included Third Security, New River Management, NewVa Capital […]

PixelOptics (Roanoke, VA) a commercial-stage developer of dynamic electronic focusing eyeglasses, closed a $35M Series D financing. Participants include Safeguard Scientifics, Delphi Ventures, Carlyle Group, Longitude Capital and Stark Investments.

Kerederm (Blacksburg, VA) a development-stage medical device company focused on the use of germicidal phototherapy to prevent and treat skin and nail infections, closed a $2.5M Series A financing. Participants include NewVa Capital Partners. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Intrexon (Blacksburg, VA) a clinical-stage biopharmaceutical company focused on modular inducible cancer immunotherapeutics, closed a $10M Series C bring the total round financing to date of $35M. Participants include New River Management.

  

to top of page...